Last reviewed · How we verify
Vi-TT
Vi-TT is a typhoid conjugate vaccine that stimulates immune responses against Salmonella typhi by presenting the polysaccharide capsule antigen conjugated to a protein carrier.
Vi-TT is a typhoid conjugate vaccine that stimulates immune responses against Salmonella typhi by presenting the polysaccharide capsule antigen conjugated to a protein carrier. Used for Prevention of typhoid fever caused by Salmonella typhi.
At a glance
| Generic name | Vi-TT |
|---|---|
| Also known as | Typbar TCV |
| Sponsor | International Vaccine Institute |
| Drug class | Typhoid conjugate vaccine |
| Target | Salmonella typhi Vi polysaccharide antigen |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains the Vi polysaccharide antigen from Salmonella typhi conjugated to tetanus toxoid (TT), which enhances immunogenicity by promoting T-cell dependent B-cell responses. This conjugate approach improves antibody production and immunological memory compared to unconjugated polysaccharide vaccines, providing protection against typhoid fever.
Approved indications
- Prevention of typhoid fever caused by Salmonella typhi
Common side effects
- Injection site pain or erythema
- Fever
- Headache
- Myalgia
Key clinical trials
- Evaluation of Typhoid Conjugate Vaccine Effectiveness in Ghana (PHASE4)
- Co-administration Study of OCV, TCV and MR (PHASE3)
- Effectiveness of a Typhoid Conjugate Vaccine in DRC (PHASE4)
- Typhoid Conjugate Vaccine Introduction in Navi Mumbai, India
- Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases
- Safety, Immunogenicity and Compatibility With DTP of a Typhoid Fever Vaccine in Infants (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vi-TT CI brief — competitive landscape report
- Vi-TT updates RSS · CI watch RSS
- International Vaccine Institute portfolio CI